Did anyone see this? Looks like a another name change coming and new management.
Global Media Networks, Inc. Signs Takeover Agreement With Biocure Med Inc.
MarketWire News ReleasesPublished: 02/20/08 08:30 AM ESTReleased By:
Global Media Networks, Inc.
Rating:
Related Stocks:
GLMN
NewsvineCommentBiocure Med Inc. Is an Israel-Based Biotech Corporation
PRAEKASA MUENG, THAILAND -- (MARKET WIRE) -- 02/20/08 -- Global Media Networks, Inc. (GLMN), a technology Company, today announced that it has signed a definitive agreement to be taken over by Biocure Med Inc., an Israel-based Biopharmaceutical Corporation.
Global Media Networks Inc. was formerly a Corporation with interests in the publishing, encoding, streaming and telecommunications industry. Mr. Chatpoom Thanomlek, President, stated the following: "I am very pleased for all the shareholders, in terms of the tremendous value and opportunity that this takeover represents to them. The new management and board members will be officially elected as soon as the name change becomes effective. In the meantime, operations are being readied as the filings are taking place. New management has made available to shareholders and clients the in-progress Corporate Website at: www.biocuremed.com."
About Biocure Med Inc.
Biocure Med Inc. (Biocure) is a biotechnology company specialized in the research, discovery, development and commercialization of medication that potentially cure or stabilize diseases and respond to patients' medical needs. Biocure's proprietary medication product lines under development are centered on the treatment of Diabetes and Alzheimer's disease. Biocure's goal and vision is to become a major player and the world's leading developer of breakthrough therapeutic products in the biotechnology industry.
During the last 12 years, Biocure has been built into a fully integrated, commercial-stage biopharmaceutical company that invents, develops and markets safe and effective drugs to treat patients with chronic, debilitating and life-threatening diseases, primarily Diabetes and Alzheimer's. Biocure's new public venue will allow it to expand and rapidly distribute its new breakthrough products in North America and Europe.
Please note that the Press Release distributed by Global Media Networks, Inc. on February 13, 2008 was issued in error and prior to complete verification of data on the Corporate website. The Feb. 13 Press Release has been replaced by the above Press Release. We apologize to all shareholders for any inconvenience or misunderstanding caused by this error.
For more information please visit the new in-progress Corporate Website at www.biocuremed.com.
To speak with Investor Relations, shareholders may call: David L. Baseheart at 613-482-1778 or via email at ir@biocuremed.com.
Forward-Looking Statements
Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.
Contact:
David L. Basehart
Investor Relations
Phone: 613-482-1778
E-mail: ir@biocuremed.com
URL: www.biocuremed.com
Anything I post- is my opinion!
